1.Adjusting method for data obtained from different biochemical analyzers
Yun LIN ; Jianrong ZHANG ; Qian SHEN ; Gusheng TANG
Academic Journal of Second Military Medical University 2000;0(08):-
Objective To evaluate and eliminate the potential bias between data obtained from dry and liquid biochemical assays,making data obtained by different assays matchable.Methods Bias estimation was performed based on document EP9-A2.Simple data comparison and methodology validation were performed after the experiment methods were modified with the estimated correction factors and interception.All the collected data were analyzed by EXCEL2007 software.Results The predicted bias of 4 of the 10 compared items exceeded their corresponding acceptable bias.After being adjusted by the coefficient and interception obtained from linear regression analysis,the four bias was improved and was within the acceptable range.The results of simple data comparison further confirmed this comparability.Conclusion Based on EP9-A2,we have established a protocol to obtain a consistency of data from different biochemical analyzers,which makes it possible that the detection results of the same patient from different detection systems can be used directly.The protocol has been approved by the experts during the medicinal laboratory accreditation of ISO15189.
2.Study of Reagents of Biotin-Avidin System and Their Applications Ⅴ.The Detection of Antibodies to Cell Surface Antigens with ABC-ELISA
Shaokang LI ; Gusheng ZHANG ; Yun ZHOU ; Yuejian WANG
Chinese Journal of Immunology 1985;0(02):-
Two reaction systems have been observed to ascertain the capability of ABC-ELISA on the detection of antibodies against particulate antigens.Mouse thymucytes as the antigens were coated on the enzyme immunoassay plate for one system,and rabbit anti- mouse brain serum was titrated.The titer of the serum in ABC-ELISA was 1:12,800, about 40-fold higher than that in complement dependent cytotoxicity assay.In the other system,the plate was coated with cultured human leukemia cells of T lymphocyte origin(Cem-T)and B cell origin(Daudi),where the ascites induced by an anti-human lymphocyte hybridoma was titrated.The results showed that ABC-ELISA was 8-16 times sensitive than the standard ELISA,while the specificity and reliability of ABC- ELISA seemed satisfectory.The experi mental condition that might reduce nonspeci- ficity of the reaction to a certain degree was discussed.
3.Finite-element investigation on center of resistance of maxillary anterior teeth.
Jiehua SU ; Jiali LIU ; Duangqiang ZHANG ; Gusheng LUO ; Libing CHEN ; Xiaonan YU ; Zhiwei LIN ; Jian ZHANG
Journal of Biomedical Engineering 2014;31(5):994-1000
A three-dimensional finite element model of premaxillary bone and anterior teeth was established with ANSYS 13.0. The anterior teeth were fixed with strong stainless labial archwire and lingual frame. In the horizontal loading experiments, a horizontal retraction force of 1.5 N was applied bilaterally to the segment through hooks at the same height between 7 and 21 mm from the incisal edge of central incisor; in vertical loading experiments, a vertical intrusion force of 1.5 N was applied at the midline of lingual frame with distance between 4 and 16 mm from the incisal edge of central incisor. After loading, solution was done and displacement and maximum principle stress were calculated. After horizontal loading, lingual displacement and stress in periodontal membrane (PDM) was most homogeneous when the traction force was 14 mm from the edge of central incisor; after vertical loading, intrusive displacement and stress in PDM were most homogeneous when the traction force was 12 mm from the incisal edge of central incisor. The results of this study suggested that the location of center of resistance (CRe) of six maxillary anterior teeth is about 14 mm gingivally and 12 mm lingually to incisal edge of central incisor. The location can provide evidence for theoretical and clinical study in orthodontics.
Dental Models
;
Dental Stress Analysis
;
Finite Element Analysis
;
Humans
;
Incisor
;
Maxilla
;
Periodontal Ligament
;
Tongue
4.Mutational profile of myeloproliferative neoplasms detected by a customized NGS-based gene panel
Xiu HUANG ; Xuan DENG ; Xiao XU ; Xinju ZHANG ; Yuesheng ZHANG ; Weizhe MA ; Tingting HU ; Gusheng TANG ; Ming GUAN
Chinese Journal of Laboratory Medicine 2019;42(6):427-434
Objective By a sequencing panel consisting of 50 targeted genes, aiming at depicting the molecular landscape of ET, PV, and PMF, which are three major subtypes of MPN, to provide valuable information in the diagnosis and prognosis of MPN.Methods A retrospective study was conducted of 53 patients from Huashan hospital and Changhai hospital. All patients were diagnosed in accordance with the 2016 WHO diagnostic criteria for MPN, including 31 cases of ET(11 males, 20 females, median age 55 years), 17 cases of PV(12 males, 5 females, median age 65 years), and 5 cases of PMF(4 males, 1 females, median age 67 years), and underwent next-generation of DNA sequencing of their bone marrow or blood samples. The genetic analyses were performed on bone marrow or peripheral blood. Referring to COSMIC, dbSNP, Clinvar and other public databases, we analyzed the sequencing data, and elucidated the mutation profile of MPN patients, combining with their clinic information. Results In addition to the typical JAK2, CALR, and MPL mutations, pathogenic mutations in other 11 genes were detected, as well as 4 SNPs that confer individual susceptibility to MPNs (rs4858647, rs9376092, rs58270997, rs621940). The average rate of mutated genes was 2.3 genes per patient. In all patients (53 cases), the mutated genes detected were TET2, EZH2, ASXL1, MIR662, SF3B1, BARD1, DNMT3A, KIT, RUNX1, TP53, NRAS according to their mutational frequency. Conclusions Applying next-generation sequencing technology, multi-gene sequencing of a bunch of typical BCR-ABL-negative MPN patients can be performed at one time within 2 working days, and pathogenic mutations other than JAK2, CALR, MPL can be found, which has a bright prospection in clinic.
5.Acute promyelocytic leukemia with NPM鄄RARα fusion gene positive: report of one case and review of literature
Jiawei WU ; Mengqiao GUO ; Shenglan GONG ; Gusheng TANG ; Min LIU ; Jing DING ; Yuesheng ZHANG ; Jianmin WANG ; Jianmin YANG ; Hui CHENG
Journal of Leukemia & Lymphoma 2019;28(4):215-218
Objective To investigate the diagnosis, treatment and prognosis of acute promyelocytic leukemia (APL) with NPM_RARα fusion gene positive. Methods One APL patient with NPM_RARα fusion gene positive who was diagnosed by using morphology, immunology, cytogenetics, molecular biology and multiplex fluorescence in situ hybridization in Changhai Hospital in November 2014 was retrospectively analyzed, and the patient was induced with retinoic acid and treated with DA (daunorubicin + cytarabine) regimen, followed by 4 courses of cytarabine consolidation therapy. Results Abnormal promyelocyte accounted for 0.64 by morphology. And the group of cells expressed myeloperoxidase (MPO), CD13, CD15, CD117, and CD7, CD11c, CD79a, CD123 weakly expressed or not by immunophenotype analysis; karyotype analysis showed 45, XY, t(5;17), 7p-,-16[8]/46, idem,+20[5]/45, idem,-8,+20[2]/46, XY[5]; the fusion gene screening showed that the expression level of NPM_RARα was 416.98% compared with that of APL; molecular complete remission was obtained after the consolidation therapy, but the patient relapsed after 34 months. Finally, the patient died of abnormal coagulation and respiratory failure, with overall survival of 35 months. Conclusion APL with NPM_RARα fusion gene positive is a rare type of acute leukemia, and the main treatment method is retinoic acid combined with myeloid chemotherapy regimen, which has a favorable efficacy but a poor prognosis.
6. The study of expression and prognostic value of CD123 in acute myeloid leukemia bone marrow blasts
Wenqin YUE ; Gusheng TANG ; Min LIU ; Hui CHENG ; Jing DING ; Tao WANG ; Jianmin WANG ; Xiaoxia HU ; Weiping ZHANG ; Li CHEN ; Jianmin YANG
Chinese Journal of Hematology 2017;38(10):876-882
Objective:
To study the expression of CD123 in bone marrow (BM) blasts of acute myeloid leukemia (AML) patients to explore the relationship between CD123 expression and therapeutic response and prognosis.
Methods:
This study retrospectively analyzed expression and distribution of CD123 in BM blasts in 137 cases of newly diagnosed AML (excluded M3) , CD123 detected by flow cytometry≥20% was defined as positive, including 84 CD123+ AML and 53 CD123- AML, efficacy and prognosis were compared between the two groups.
Results:
① Among 137 patients, 84 were in group CD123+ (61.3%) , and 53 in group CD123- (38.7%) . All 137 patients were classified into risk groups based on cytogenetic and molecular biology abnormalities. No significant differences were seen between the three risk groups with regard to their CD123 levels (
7.Clinical significance of PDGFRβ gene testing in hematological tumors.
Mengqiao GUO ; Fangyu GUO ; Yan ZHANG ; Hui CHENG ; Gusheng TANG ; Zhengxia HUANG ; Shenglan GONG
Chinese Journal of Medical Genetics 2023;40(11):1334-1339
OBJECTIVE:
To explore the clinical and laboratory characteristics of hematological tumors with different types of abnormalities in platelet derived growth factor β (PDGFRβ) gene.
METHODS:
A retrospective analysis was carried out on 141 patients with abnormal long arm of chromosome 5 (5q) and comprehensive medical history data from Changhai Hospital Affiliated to Naval Medical University from 2009 to 2020, and their clinical data were collected. R-banding technique was used for chromosomal karyotyping analysis for the patient's bone marrow, and fluorescence in situ hybridization (FISH) was used to detect the PDGFRβ gene. The results of detection were divided into the amplification group, deletion group, and translocation group based on FISH signals. The three sets of data column crosstabs were statistically analyzed, and if the sample size was n >= 40 and the expected frequency T for each cell was >= 5, a Pearson test was used to compare the three groups of data. If N < 40 and any of the expected frequency T for each cell was < 5, a Fisher's exact test is used. Should there be a difference in the comparison results between the three sets of data, a Bonferroni method was further used to compare the data.
RESULTS:
In total 98 patients were detected to have PDGFRβ gene abnormalities with the PDGFRβ probe, which yielded a detection rate of 69.50% (98/141). Among these, 38 cases (38.78%) had PDGFRβ gene amplifications, 57 cases (58.16%) had deletions, and 3 (3.06%) had translocations. Among the 98 cases, 93 were found to have complex karyotypes, including 37 cases from the amplification group (97.37%, 37/38), 55 cases from the deletion group (96.49%, 55/57), and 1 case from the translocation group (33.33%, 1/3). Analysis of three sets of clinical data showed no significant gender preponderance in the groups (P > 0.05). The PDGFRβ deletion group was mainly associated with myeloid tumors, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (P < 0.001). The PDGFRβ amplification group was more common in lymphoid tumors, such as multiple myeloma (MM) (P < 0.001). The PDGFRβ translocation group was also more common in myelodysplastic/myeloproliferative tumors (MDS/MPN).
CONCLUSION
Tumors with PDGFRβ gene rearrangement may exhibit excessive proliferation of myeloproliferative tumors (MPN) and pathological hematopoietic changes in the MDS, and have typical clinical and hematological characteristics. As a relatively rare type of hematological tumor, in addition to previously described myeloid tumors such as MPN or MDS/MPN, it may also cover lymphoid/plasma cell tumors such as multiple myeloma and non-Hodgkin's lymphoma.
Humans
;
Clinical Relevance
;
Hematologic Neoplasms/genetics*
;
In Situ Hybridization, Fluorescence
;
Multiple Myeloma
;
Myelodysplastic Syndromes
;
Retrospective Studies
;
Translocation, Genetic
8. Effect of consolidation before allogeneic hematopoietic stem cell transplantation for non-favorable acute myeloid leukemia patients with first complete remisson and negative minimal residual disease
Yimin ZHANG ; Ying ZHANG ; Xiong NI ; Lei GAO ; Huiying QIU ; Yuesheng ZHANG ; Gusheng TANG ; Jie CHEN ; Weiping ZHANG ; Jianmin WANG ; Jianmin YANG ; Xiaoxia HU
Chinese Journal of Hematology 2020;41(1):16-22
Objective:
To probe the prognostic value of consolidation chemotherapy in non-favorable acute myeloid leukemia (AML) patients who were candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT) with first complete remission (CR1) and negative minimal residual disease (MRD-) .
Methods:
A retrospective analysis was conducted on 155 patients with non-favorable AML who received allo-HSCT in CR1/MRD- from January 2010 to March 2019. The survival data were compared between patients who received and those not received pre-transplant consolidation chemotherapy.
Results:
A total of 102 patients received pre-transplant consolidation chemotherapy (consolidation group) , and 53 cases directly proceeded to allo-HSCT when CR1/MRD- was achieved (nonconsolidation group) . The median ages were 39 (18-56) years old and 38 (19-67) years old, respectively. Five-year post-transplant overall survival [ (59.3±7.5) %
9. Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old
Aijie HUANG ; Libing WANG ; Juan DU ; Gusheng TANG ; Hui CHENG ; Shenglan GONG ; Lei GAO ; Huiying QIU ; Xiong NI ; Jie CHEN ; Li CHEN ; Weiping ZHANG ; Jianmin WANG ; Jianmin YANG ; Xiaoxia HU
Chinese Journal of Hematology 2019;40(8):625-632
Objective:
To compare the difference of efficacy between traditional Hyper-CVAD/MA regimen and the adolescents inspired chemotherapy regimen, CH ALL-01, in treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) .
Methods:
In this study we retrospectively analyzed 158 Ph+ ALL patients receiving Hyper-CVAD/MA regimen (
10. Prognostic value of donor chimerism at +90 days after allogeneic hematopoietic stem cell transplantation in young patients with intermediate-risk acute myeloid leukemia
Yang FEI ; Xiaoxia HU ; Qi CHEN ; Aijie HUANG ; Hui CHENG ; Xiong NI ; Huiying QIU ; Lei GAO ; Gusheng TANG ; Jie CHEN ; Weiping ZHANG ; Jianmin YANG ; Jianmin WANG
Chinese Journal of Hematology 2019;40(12):990-995
Objective:
To investigate the relationship between donor chimerism and relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) .
Methods:
The clinical data of 105 patients with acute myeloid leukemia (AML) who underwent allo-HSCT and recurrence-free survival>90 days from January 2010 to January 2019 were retrospectively analyzed. The bone marrow samples were collected at 15, 30, 60, 90, 180, 270, 360 days after transplantation. Donor chimerism was detected by single nucleotide polymorphism (SNP) -PCR.
Results:
Of the 105 patients, 43 cases were male and 62 cases were female, with a median age of 38 (16-60) years. Till April 2019, the median follow-up was 843 (94-3 261) days. Ninety days after transplantation, 18 cases relapsed, 33 cases died, and 72 cases survived. The 3-year overall survival (OS) rate was (66.8±5.1) %, and the recurrence-free survival (RFS) rate was (65.1±5.0) %. Pre-transplant disease status, pre-transplant minimal residual disease (MRD) , and 90 day post-transplantation chimerism were independent risk factors related to RFS. The risk of recurrence was significantly increased in patients with a donor chimerism rate ≤97.24% at 90 days after transplantation[